期刊文献+

赖诺普利联合坎地沙坦治疗心力衰竭合并原发性高血压(英文) 被引量:2

Clinical Observation on the Lisinopril plus Candesartan in the Treatment of Heart Failure Combined with Essential Hypertension
原文传递
导出
摘要 目的:观察和评价赖诺普利联合坎地沙坦治疗心力衰竭(HF)合并原发性高血压(EH)的疗效。方法:将我院收治的EH合并HF患者69例,在给予个体化治疗的基础上随机分为:A组赖诺普利治疗组,B组坎地沙坦治疗组,C组赖诺普利和坎地沙坦联合治疗组,三组疗程均为8周。观察治疗前后的血压、心功能分级、BNP水平、心脏彩色多普勒及肝肾功检查。结果:与对照组比较,联合组的总有效率明显增高,差异有统计学意义;治疗前后所有患者肝肾功能等生化指标未见明显变化。结论:赖诺普利与坎地沙坦联合治疗心力衰竭合并原发性高血压的疗效明显优于单用赖诺普利或坎地沙坦的疗效,且安全性好,值得广泛推广和应用。 Objective: To observe and evaluate the efficacy and safety of clinical observation on the Lisinopril plus Candesartan in the treatment of heart failure(HF)combined with essential hypertension(EH). Methods: 69 patients with heart failure and hypertension were enrolled and randomly divided into three groups on the basis of different medications: The patients in group A were treated by the Lisinopril for 8 weeks, while the patients in group B were treated by the Candesartan for 8 weeks and the patients in group C were treated by the Lisinopril combined with the Candesartan for 8 weeks. Then the heart function which referred to the blood pressure, the NYHA classification, the level of brain natriuretic peptide (BNP), the echocardiography and the function of liver and kidney of patients were observed and compared among the three groups before and after the treatment. Results: Compared with group A and group B, the total effective rate of group C was improved obviously (P〈0.05), and there ~vas no significant difference in biochemical indexes before and after treatment between the three groups (P〉0.05). Conclusion: The efficacy of Lisinopril combined with Candesartan in the treatment of heart failure and hypertension was much better than that of the single dosage of Lisinopril or Candesartan, which was worthy of being promoted in clinical trials.
出处 《现代生物医学进展》 CAS 2014年第31期6135-6138,共4页 Progress in Modern Biomedicine
关键词 赖诺普利 坎地沙坦 心力衰竭 高血压 联合治疗 Lisinopril Candesartan Heart failure Hypertension Combined therapy
  • 相关文献

参考文献2

二级参考文献15

  • 1周楠,沈颖.抑制血管紧张素Ⅱ药物的肾保护研究[J].国外医学(泌尿系统分册),2004,24(6):807-810. 被引量:5
  • 2胡茂清,张执玉.糖尿病肾病的合理治疗[J].四川省卫生管理干部学院学报,2005,24(4):286-289. 被引量:6
  • 3张宝生,徐延光,卢军,赵伟,窦红梅,张廷威.低剂量雷米普利对2型糖尿病肾病患者尿蛋白的影响[J].中国中西医结合肾病杂志,2006,7(9):532-534. 被引量:6
  • 4施仲伟.正确解读ONTARGET试验的结果[J].中国处方药,2008,(74):69-71.
  • 5[2]Makino H,Nakamura Y,Wada J.Remission and regression of diabetic nephropathy[J].Hypertens Res,2003,26(7):515-519.
  • 6[6]Gilbert RE,Cox A,Wu LL,et al.Expression of transforming groth-factor-β1 and type Ⅳcollagen in the tubulointerstitrum in experimental diabetes effects of ACE inhibition[J].Diabets,1998,47(3):414-422.
  • 7[7]Ulicna O,Cizova M,Kolesar P,et al.Bioenergetics of livermitochondria after administration of ramipril in experimental diabetsmellitus[J].Bratisl Lek Listy,1997,98(12):687-691.
  • 8[8]Lew is EJ,Hunsicker LG,ClarkeWR,et al.Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropatay duo to type 2 diabeters[J].NEngl JMed,2001,345(12):851-855.
  • 9[9]Laverman GD,Remuaai G,Ruggenenti P.ACE inhibition versus angiotensin receptor blockade:which is better for renal and cardiovascular protection[J].J Am Soc Nephrol,2004,15(1):64-70.
  • 10侯英,滕海坤,杨玉芝.厄贝沙坦治疗2型糖尿病早期肾病的临床观察[J].放射免疫学杂志,2008,21(3):256-257. 被引量:12

共引文献15

同被引文献20

引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部